Main Content


Study title

Risk based, response adapted, phase 2 open label trial of nivolumab + brentuximad vedotin for children adolescents and young adults with relapsed/refractory CD30 classic Hodgkin lymphoma

  • Principal Investigator: Dr. Anderson Collier


This study is looking at how well certain experimental drugs work in children and adolescents with classical Hodgkin’s lymphoma.

Who can participate

Those eligible to participate in this study include:

  • Males and females, ages 5-30, with confirmed classical Hodgkin’s lymphoma (cHL), excluding nodular lymphocyte-predominant cHL, after failure of or non-response to first-line therapy.

For more information

  • Maggie Goad
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson MS 39216
    (601) 815-9390 
  • IRB Number: 2017-0165